Intercytex raises £12M in new venture round
The UK's Intercytex has raised £12 million in new venture capital. Avlar BioVentures, Merlin Biosciences, 3i, Cambridge Gateway Partnership, NIF Ventures and Scottish Equity Partners all participated in the round. The financing will be used to complete Phase III trials of ICX-PRO, Intercytex's active woundcare product, take ICX-TRC, its hair regeneration product, through later stage clinical trials and to move ICX-SKN, a living skin replacement, into the clinic. "We are extremely pleased to have raised this considerable sum which allows us to significantly advance all our projects," said Nick Higgins, Intercytex's CEO.
- read this press release for more
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets